NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Granules India Allots Equity and Warrants Worth Rs 1,762.5 Cr at Rs 585/Share
Granules India has successfully allotted 51.28 lakh equity shares to institutional investors and 2.5 crore convertible warrants to the promoter group and select non-promoters. The allotment was priced at Rs 585 per share/warrant, with the company immediately raising Rs 300 crore from equity and Rs 365.6 crore as a 25% upfront warrant payment. This significant capital infusion, largely backed by the promoter group, indicates strong internal confidence and provides a substantial war chest for future growth. On a fully diluted basis, the total share capital will increase to 27.28 crore shares.
முக்கிய அம்சங்கள்
Allotted 51,28,205 equity shares at Rs 585 each, raising Rs 300 crore from 360 ONE institutional funds.Issued 2,50,00,000 convertible warrants at Rs 585 each, with 25% (Rs 365.62 crore) received upfront.Promoter group subscribed to the majority of warrants, with Mrs. Chigurupati Uma Devi taking 2.48 crore warrants.Total potential capital to be raised via warrants is Rs 1,462.5 crore within an 18-month conversion window.Paid-up equity capital increased to Rs 24.78 crore and will reach Rs 27.28 crore on a fully diluted basis.
👀 கவனிக்க வேண்டியவை
Investors should view the promoter participation at Rs 585 as a strong signal of confidence in the company's valuation and future prospects. Monitor upcoming quarterly results for commentary on how this capital will be deployed for expansion or debt management.
Granules India to Issue 2.5 Cr Warrants and 51.28 Lakh Equity Shares via Preferential Issue
Granules India has received shareholder approval for a significant fundraise through a preferential issue of securities. The company plans to issue up to 2,50,00,000 convertible warrants and 51,28,205 equity shares to specific investors. The pricing will be subject to recomputation as per SEBI ICDR Regulations if required. Until the proceeds are fully utilized for their intended objects, the funds will be parked in low-risk instruments like debt mutual funds and government securities.
முக்கிய அம்சங்கள்
Authorized issuance of up to 2,50,00,000 warrants convertible into equity sharesAuthorized issuance of up to 51,28,205 equity shares on a preferential basisShareholder approval for the resolutions was obtained in the EGM held on January 22, 2026Pricing of securities to be recomputed in compliance with SEBI ICDR Regulations where necessaryUnutilized proceeds to be temporarily invested in debt mutual funds, bank deposits, or government securities
👀 கவனிக்க வேண்டியவை
Investors should track the final allotment price and the specific end-use of funds to assess the long-term growth potential versus equity dilution. The move indicates a strong intent to raise capital for expansion or balance sheet strengthening.
Granules India Q3 FY26: Revenue Up 22% to ₹1,388 Cr, EBITDA Grows 34% with Margin Expansion
Granules India reported a strong Q3 FY26 with revenue growing 22% YoY to ₹1,388 crores, driven by robust performance in North America and Europe. EBITDA increased 34% to ₹308 crores, with margins expanding to 22.2% despite a ₹24.8 crore loss in the nascent Peptide CDMO segment. The company is making steady progress on regulatory remediation at its Gagillapur facility, following a constructive meeting with the US FDA in January 2026. Additionally, shareholders have approved a preferential issue to strengthen the balance sheet and fund future capacity expansions.
முக்கிய அம்சங்கள்
Revenue grew 22% YoY to ₹1,388 crores, while EBITDA rose 34% to ₹308 crores.Gross margins improved by 216 bps YoY to 63.9% due to a better product mix in finished dosages.Gagillapur remediation is on track with no concerns raised by the FDA regarding the pace of corrective actions.Net debt stood at ₹1,015 crores with a cash-to-cash cycle of 202 days.Peptide CDMO business (Ascelis) is expected to see meaningful improvement in Q4 FY26 following project deliveries.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final resolution of the Gagillapur warning letter and the commercial scale-up of the high-margin Peptide CDMO business. The company's focus on complex generics and integrated manufacturing continues to drive operational leverage.
Granules India Q3FY26: Revenue Up 22% YoY to ₹13,879 Mn, PAT Grows 28%
Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and scaling of the complex generics portfolio. The company maintained a healthy ROCE of 16.8% and reduced its Net Debt/EBITDA ratio to 0.91x.
முக்கிய அம்சங்கள்
Revenue increased 22% YoY to ₹13,879 Mn, with Europe sales surging 131% YoY to ₹2,344 Mn.EBITDA grew 34% YoY to ₹3,081 Mn, with margins improving to 22.2% from 20.2% in the previous year.Finished Dosage (FD) segment continues to dominate, contributing 76% of total revenue.Complex generics portfolio expanded, driven by the scale-up of the ADHD portfolio in the US market.US Packaging facility completed FDA inspection with zero observations, and ANVISA Brazil GMP certificate was received for the Gagillapur site.
👀 கவனிக்க வேண்டியவை
The company's strategic shift toward complex generics and finished dosages is yielding higher margins and robust growth. Investors should maintain a positive outlook given the strong regulatory compliance record and expanding presence in high-value markets like Europe.
Granules India Q3 FY26 Net Profit Rises 23.8% YoY to ₹1,115.8M; Plans ₹17,625M Fundraising
Granules India reported a 6.3% YoY increase in standalone revenue to ₹8,953.18 million for Q3 FY26, with net profit growing 23.8% to ₹1,115.82 million. The company is navigating challenges from a USFDA warning letter at its Gagillapur facility, which has led to higher remediation costs and production slowdowns. A significant fundraising plan of approximately ₹17,625 million through warrants and equity at ₹585 per share has been approved to support growth. Additionally, the company completed the acquisition of Granules Pharmaceuticals GmbH in Germany and accounted for costs related to the Senn Chemicals AG acquisition.
முக்கிய அம்சங்கள்
Standalone Net Profit increased by 23.8% YoY to ₹1,115.82 million in Q3 FY26.Total Revenue from operations grew 6.3% YoY to ₹8,953.18 million.Approved fundraising of ₹14,625 million via convertible warrants and ₹3,000 million via equity at ₹585/share.Exceptional item of ₹121.60 million recorded for Senn Chemicals AG acquisition costs.Ongoing remediation at Gagillapur facility following USFDA warning letter continues to impact margins via higher consultancy and freight costs.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the USFDA remediation at the Gagillapur plant and the utilization of the ₹17,625 million fundraise. The growth in profit despite regulatory hurdles is a positive sign, but the high remediation costs remain a near-term drag.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Granules India Shareholders Approve Issuance of 2.5 Crore Warrants and 51.28 Lakh Equity Shares
Granules India Limited held an Extraordinary General Meeting (EGM) on January 22, 2026, where shareholders approved two significant capital-raising resolutions. The first resolution involves the issuance of up to 2.5 crore warrants convertible into equity shares on a preferential basis, which passed with 86.69% support. The second resolution for the issuance of up to 51.28 lakh equity shares on a preferential basis received near-unanimous approval at 99.99%. These approvals provide the company with a mandate to raise capital through preferential allotments, likely aimed at funding future growth or strategic initiatives.
முக்கிய அம்சங்கள்
Approved issuance of up to 2,50,00,000 warrants convertible into equity shares on a preferential basis.Approved issuance of up to 51,28,205 equity shares on a preferential basis.Warrant resolution passed with 86.69% majority, while the equity share resolution saw 99.99% approval.A total of 73 shareholders participated in the meeting held via video conferencing.The voting results were consolidated from both remote e-voting and e-voting during the EGM.
👀 கவனிக்க வேண்டியவை
Investors should look for subsequent disclosures regarding the allotment price and the specific identity of the allottees to assess potential equity dilution. The successful passage of these resolutions indicates strong shareholder backing for the company's capital expansion plans.
Granules India Issues Corrigendum for Rs 1,762.5 Cr Fundraise; Re-allocates Shares to 360 ONE Funds
Granules India has issued a corrigendum to its EGM notice regarding a preferential issue of equity shares and warrants totaling approximately Rs 1,762.5 crore. The primary change involves the removal of the Public Sector Pension Investment Board from the allottee list, with their portion re-allocated to various 360 ONE funds. The total issue size remains unchanged, and the proceeds are earmarked for capital expenditure, debt prepayment for its subsidiary Granules Life Sciences, and working capital. India Ratings & Research has been appointed as the monitoring agency for the fund utilization.
முக்கிய அம்சங்கள்
Total fundraise size remains unchanged at approximately Rs 1,762.5 crore via equity and warrants.Public Sector Pension Investment Board removed as an allottee; shares re-allocated to 360 ONE funds.Rs 315 crore allocated for prepayment of term loans for subsidiary Granules Life Sciences Private Limited.Rs 300 crore designated for capital expenditure in fixed assets, infrastructure, and technology over 24 months.India Ratings & Research Private Limited appointed as the monitoring agency for issue proceeds.
👀 கவனிக்க வேண்டியவை
Investors should monitor the EGM outcome on January 22, 2026, as the capital infusion will significantly reduce debt and fund expansion. The re-allocation to 360 ONE funds indicates continued strong institutional interest despite the removal of one specific allottee.
Granules Gets US FDA Tentative Approval for Generic Dyanavel XR with 180-Day Exclusivity
Granules India's US subsidiary has received tentative FDA approval for generic Amphetamine Extended-Release tablets, the generic version of DYANAVEL XR, used for ADHD treatment. Significantly, the company has secured 180-day exclusivity for this product, which addresses a market size of approximately USD 41 million. This marks the second major CNS-related tentative approval in weeks, following a December 2025 approval for a generic version of ADZENYS XR-ODT with a USD 172 million market. These developments highlight the company's successful pivot toward complex generics and differentiated products in the U.S. market.
முக்கிய அம்சங்கள்
Received US FDA Tentative Approval for generic Amphetamine ER tablets (gDYANAVEL XR) in 5mg, 10mg, 15mg, and 20mg strengths.Granted 180-day exclusivity by the FDA, ensuring a period of limited competition upon commercial launch.Targets an addressable market size of approximately USD 41 million for the gDYANAVEL XR equivalent.Follows a recent tentative approval for generic ADZENYS XR-ODT which has a USD 172 million market potential.Strengthens Granules' portfolio in the complex Central Nervous System (CNS) therapeutic segment.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from tentative to final approval and the subsequent launch timeline, as the 180-day exclusivity provides a high-margin opportunity. The company's growing pipeline of complex generics suggests a positive shift in its product mix toward higher-value segments.
Granules India to Raise ₹1,762.50 Cr via Preferential Issue of Warrants and Equity Shares
Granules India has scheduled an Extraordinary General Meeting on January 22, 2026, to approve a total fundraise of ₹1,762.50 crores. The company plans to issue 2.5 crore convertible warrants to the promoter group at ₹585 each, totaling ₹1,462.50 crores. Additionally, it will issue 51.28 lakh equity shares at the same price to institutional investors, including 360 ONE funds and the Public Sector Pension Investment Board, raising ₹300 crores. This significant capital infusion, largely backed by promoters, indicates strong internal confidence in the company's growth trajectory.
முக்கிய அம்சங்கள்
Issuance of 2.5 crore warrants to the promoter group at ₹585 per warrant, totaling ₹1,462.50 crores.Preferential allotment of 51.28 lakh equity shares to institutional investors at ₹585 per share, raising ₹300 crores.Total capital infusion of ₹1,762.50 crores to be approved at the EGM on January 22, 2026.Warrant terms require 25% payment upfront with the remaining 75% payable upon conversion within 18 months.Key institutional participants include various 360 ONE funds and the Public Sector Pension Investment Board.
👀 கவனிக்க வேண்டியவை
Investors should take the significant promoter participation as a positive signal of long-term commitment and confidence. Monitor upcoming disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Granules India to Raise Rs 1,762.50 Crore via Preferential Issue of Shares and Warrants
Granules India's board has approved a massive fundraise of Rs 1,762.50 crore through a mix of equity shares and convertible warrants. The company will issue 2.5 crore warrants at Rs 585 each, primarily to the promoter group, totaling Rs 1,462.50 crore. Additionally, it will issue 51.28 lakh equity shares at the same price to institutional investors like 360 ONE and Public Sector Pension Investment Board for Rs 300 crore. This capital infusion is subject to shareholder approval at an EGM scheduled for January 22, 2026.
முக்கிய அம்சங்கள்
Total fundraise of Rs 1,762.50 crore at a fixed price of Rs 585 per share/warrant.Issuance of 2.5 crore convertible warrants to promoters and others, aggregating Rs 1,462.50 crore.Issuance of 51.28 lakh equity shares to non-promoter institutional investors for Rs 300 crore.Major institutional participants include 360 ONE funds and Public Sector Pension Investment Board.Warrants require 25% upfront payment and are convertible within 18 months from allotment.
👀 கவனிக்க வேண்டியவை
Investors should view the significant promoter participation and institutional backing as a strong vote of confidence. Monitor the upcoming EGM on January 22, 2026, and the company's plans for utilizing this capital for growth.
Granules Receives US FDA Tentative Approval for Generic ADHD Drug with $172M Market Size
Granules India's US subsidiary has received tentative FDA approval for generic Amphetamine Extended-Release Orally Disintegrating Tablets, a generic version of ADZENYS XR-ODT®. The product targets the ADHD treatment market, which has an estimated annual size of USD 172 million according to IQVIA. This approval is significant as the market currently has limited competition with only one approved generic and one authorized generic available. The drug will be manufactured at the company's facility in Chantilly, Virginia, emphasizing their focus on complex dosage forms.
முக்கிய அம்சங்கள்
Received US FDA tentative approval for generic Amphetamine ER Orally Disintegrating Tablets in 6 strengths.Targets a significant US market opportunity estimated at USD 172 million per IQVIA data.Limited competition environment with only one approved generic and one authorized generic currently in the market.Product to be manufactured at Granules' US-based facility in Chantilly, Virginia.Strengthens the company's portfolio in the Central Nervous System (CNS) therapeutic area.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from tentative to final approval and the subsequent commercial launch timeline. This development strengthens Granules' US generic pipeline in a high-barrier, limited-competition segment.
Granules India Subsidiary Completes USFDA Inspection with 5 Procedural Observations
Granules India's wholly-owned subsidiary, Granules Life Sciences (GLS), underwent a USFDA inspection at its Hyderabad facility from December 15 to 19, 2025. The inspection, which covered Good Manufacturing Practices (GMP) and Prior Approval, concluded with 5 observations. Management has clarified that these observations are strictly procedural and do not relate to data integrity or product safety. The company is committed to responding to the USFDA within the stipulated timeframe to resolve these points.
முக்கிய அம்சங்கள்
USFDA inspection conducted at the Hyderabad facility (FEI: 3030495702) from December 15 to 19, 2025.The audit concluded with 5 observations related to procedural requirements.Zero observations were reported regarding data integrity or product safety, reducing the risk of severe regulatory action.The facility is operated by Granules Life Sciences Private Limited and manufactures PFI and Finished Dosages.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final classification of the inspection report; while 5 observations require attention, the lack of data integrity issues is a positive sign. Maintain a watch on the company's ability to resolve these procedural gaps without impacting future product approvals.
Granules India receives 'A' rating in Climate Change from CDP
Granules India Limited has received an 'A' rating in Climate Change from the Carbon Disclosure Project (CDP), a two-level improvement from its 'B' rating in 2024. The company also achieved a 'B' rating in Water Security and a 'B-' rating in Forests in its first disclosure. These ratings reflect Granules India's commitment to sustainability and climate responsibility. Investors should note the company's increasing focus on environmental transparency and performance, which could positively influence long-term value.
முக்கிய அம்சங்கள்
Received 'A' rating in Climate Change from CDP, up from 'B' in 2024Achieved 'B' rating in Water SecurityReceived 'B-' rating in Forests in first disclosure
👀 கவனிக்க வேண்டியவை
Investors should view this improved CDP rating as a positive signal regarding Granules India's commitment to environmental sustainability. Monitor future disclosures and initiatives related to ESG (Environmental, Social, and Governance) factors.
Granules India US Packaging Facility Clears US FDA Inspection with Zero Observations
Granules India's US-based subsidiary, Granules Consumer Health, LLC, has successfully cleared a US FDA GMP inspection with zero observations. The facility, which operates three advanced packaging lines, serves as a critical hub for the company's over-the-counter (OTC) products and controlled substances in the United States. This marks the second consecutive successful audit for the site, following a No Action Indicated (NAI) classification in March 2023. The outcome reinforces the company's regulatory compliance standing and ensures the stability of its US front-end distribution operations.
முக்கிய அம்சங்கள்
US FDA inspection of Granules Consumer Health, LLC facility completed with zero observations.Facility operates 3 advanced packaging lines for OTC products and controlled substances.Second successful FDA audit for the site, following a March 2023 NAI classification.The facility serves as the primary front-end division for Granules' OTC products in the US market.
👀 கவனிக்க வேண்டியவை
This regulatory clearance mitigates the risk of supply chain disruptions in the critical US market. Investors should view this as a validation of the company's robust quality systems and operational stability.
Granules India Opens Two R&D Centres of Excellence at IIT Hyderabad for Peptides and Engineering
Granules India has inaugurated two advanced Centres of Excellence (CoE) at the IIT Hyderabad Technology Research Park to bolster its R&D and CDMO capabilities. The Ascelis CoE focuses on peptide development and characterization, marking its first such facility in India, while the Particle Engineering CoE will focus on material science and novel drug delivery systems. These facilities aim to reduce reliance on external partners and create first-to-file opportunities in regulated markets. The company currently operates 11 manufacturing facilities globally and serves over 300 customers across 80 countries.
முக்கிய அம்சங்கள்
Inaugurated the Ascelis Center for Peptide Development and the Granules Center for Particle Engineering at IIT Hyderabad.The Ascelis CoE is the company's first Indian facility dedicated to cosmetic, therapeutic, and pharmaceutical peptide characterization.The Particle Engineering CoE focuses on polymorph research and amorphous solid dispersions to enable first-to-file opportunities.New centres will collaborate with Swiss-based Senn Chemicals to provide an integrated global peptide offering.Granules India maintains a global footprint with 11 manufacturing facilities across India, USA, and Switzerland.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's transition toward high-margin CDMO and peptide segments facilitated by these R&D investments. This move strengthens the long-term product pipeline and competitiveness in regulated markets.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
